Teva has received a negative opinion on its hybrid application for cabazitaxel from the European Medicines Agency’s committee for human medicinal products, recommending that the European Commission refuse a marketing authorization for the prostate cancer treatment.
CHMP Knocks Back Teva On Cabazitaxel Hybrid
Teva has seen its hybrid application for cabazitaxel rejected by the CHMP within the European Medicines Agency, after relying in part on data for docetaxel.
